Edonentan (BMS-207940), a selective antagonist of the endothelin A (ETA) receptor, has been proposed for the treatment of congestive heart failure.
in vivo
Edonentan (3-10 μmol/kg, orally) blocks big ET-1 pressor responses[1].
Edonentan (BMS 207940) shows improved systemic clearance (Cl) and steady-state volume of distribution (Vss) in comparison to BMS-193884 (HY-19263)[1].
